Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 667,452 shares of the company’s stock after buying an additional 18,800 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.66% of Dyne Therapeutics worth $15,725,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Jennison Associates LLC grew its position in shares of Dyne Therapeutics by 1.5% during the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after buying an additional 19,730 shares in the last quarter. abrdn plc acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth approximately $608,000. RA Capital Management L.P. grew its position in shares of Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after buying an additional 331,940 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Dyne Therapeutics by 4.8% during the third quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after buying an additional 84,760 shares in the last quarter. Finally, State Street Corp grew its position in shares of Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock worth $130,816,000 after buying an additional 440,890 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Down 1.1 %

Shares of NASDAQ DYN opened at $12.26 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $11.18 and a fifty-two week high of $47.45. The firm’s 50-day simple moving average is $13.68 and its 200 day simple moving average is $24.49. The stock has a market cap of $1.39 billion, a P/E ratio of -3.44 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 6,237 shares of company stock worth $77,760 over the last ninety days. 20.77% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of research reports. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Scotiabank initiated coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Finally, Piper Sandler decreased their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.85.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.